Literature DB >> 23027188

Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2.

Claire M Hull1, Oliver Bader, Josie E Parker, Michael Weig, Uwe Gross, Andrew G S Warrilow, Diane E Kelly, Steven L Kelly.   

Abstract

Two novel isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B (MIC, 8 μg ml(-1)) were found to be ERG2 mutants, wherein Δ(8)-sterol intermediates comprised >90% of the total cellular sterol fraction. Both harbored an alteration at Thr(121) in ERG2; the corresponding residue (Thr(119)) in Saccharomyces cerevisiae is essential for sterol Δ8-Δ7 isomerization. This constitutes the first report of C. glabrata harboring mutations in ERG2 and exhibiting reduced sensitivity to amphotericin B.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23027188      PMCID： PMC3497184          DOI： 10.1128/AAC.01145-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  30 in total

1.  Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient.

Authors:  S L Kelly; D C Lamb; M Taylor; A J Corran; B C Baldwin; W G Powderly
Journal:  FEMS Microbiol Lett       Date:  1994-09-15       Impact factor: 2.742

2.  Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.

Authors:  Claire M Martel; Josie E Parker; Oliver Bader; Michael Weig; Uwe Gross; Andrew G S Warrilow; Nicola Rolley; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

3.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

Review 4.  Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

Authors:  V Krcmery; A J Barnes
Journal:  J Hosp Infect       Date:  2002-04       Impact factor: 3.926

5.  Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.

Authors:  Christian Laggner; Claudia Schieferer; Birgit Fiechtner; Gloria Poles; Rémy D Hoffmann; Hartmut Glossmann; Thierry Langer; Fabian F Moebius
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

6.  Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae.

Authors:  M A Pfaller; S A Messer; R J Hollis
Journal:  Diagn Microbiol Infect Dis       Date:  1994-11       Impact factor: 2.803

7.  Identification of essential amino acid residues in a sterol 8,7-isomerase from Zea mays reveals functional homology and diversity with the isomerases of animal and fungal origin.

Authors:  Alain Rahier; Sylvain Pierre; Geneviève Riveill; Francis Karst
Journal:  Biochem J       Date:  2008-09-01       Impact factor: 3.857

8.  A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata.

Authors:  Patrick Vandeputte; Guy Tronchin; Gérald Larcher; Emilie Ernoult; Thierry Bergès; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

Review 9.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility.

Authors:  A Geber; C A Hitchcock; J E Swartz; F S Pullen; K E Marsden; K J Kwon-Chung; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191
View more
  23 in total

1.  Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis.

Authors:  Jeffrey M Rybak; C Michael Dickens; Josie E Parker; Kelly E Caudle; Kayihura Manigaba; Sarah G Whaley; Andrew T Nishimoto; Arturo Luna-Tapia; Sujoy Roy; Qing Zhang; Katherine S Barker; Glen E Palmer; Thomas R Sutter; Ramin Homayouni; Nathan P Wiederhold; Steven L Kelly; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Sphingolipid biosynthetic pathway genes FEN1 and SUR4 modulate amphotericin B resistance.

Authors:  Sushma Sharma; Md Alfatah; Vinay K Bari; Yashpal Rawal; Sanjoy Paul; K Ganesan
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

3.  Multidrug Transporters and Alterations in Sterol Biosynthesis Contribute to Azole Antifungal Resistance in Candida parapsilosis.

Authors:  Elizabeth L Berkow; Kayihura Manigaba; Josie E Parker; Katherine S Barker; Stephen L Kelly; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

4.  Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations.

Authors:  Rasmus Hare Jensen; Karen Marie Thyssen Astvad; Luis Vale Silva; Dominique Sanglard; Rene Jørgensen; Kristian Fog Nielsen; Estella Glintborg Mathiasen; Ghazalel Doroudian; David Scott Perlin; Maiken Cavling Arendrup
Journal:  J Antimicrob Chemother       Date:  2015-05-27       Impact factor: 5.790

5.  ERG6 and ERG2 Are Major Targets Conferring Reduced Susceptibility to Amphotericin B in Clinical Candida glabrata Isolates in Kuwait.

Authors:  Suhail Ahmad; Leena Joseph; Josie E Parker; Mohammad Asadzadeh; Steven L Kelly; Jacques F Meis; Ziauddin Khan
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 6.  Mechanisms of Candida Resistance to Antimycotics and Promising Ways to Overcome It: The Role of Probiotics.

Authors:  Konstantin A Demin; Aleksandr G Refeld; Anna A Bogdanova; Evgenya V Prazdnova; Igor V Popov; Olga Yu Kutsevalova; Alexey M Ermakov; Anzhelica B Bren; Dmitry V Rudoy; Vladimir A Chistyakov; Richard Weeks; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2021-03-18       Impact factor: 4.609

Review 7.  What 'Omics can tell us about antifungal adaptation.

Authors:  Gabriela Fior Ribeiro; Eszter Denes; Helen Heaney; Delma S Childers
Journal:  FEMS Yeast Res       Date:  2022-01-11       Impact factor: 2.923

8.  Plasma Membrane Proteolipid 3 Protein Modulates Amphotericin B Resistance through Sphingolipid Biosynthetic Pathway.

Authors:  Vinay K Bari; Sushma Sharma; Md Alfatah; Alok K Mondal; K Ganesan
Journal:  Sci Rep       Date:  2015-05-12       Impact factor: 4.379

9.  Fitness trade-offs restrict the evolution of resistance to amphotericin B.

Authors:  Benjamin Matteson Vincent; Alex Kelvin Lancaster; Ruth Scherz-Shouval; Luke Whitesell; Susan Lindquist
Journal:  PLoS Biol       Date:  2013-10-29       Impact factor: 8.029

10.  Synergistic effects of tacrolimus and azole antifungal compounds in fluconazole-susceptible and fluconazole-resistant Candida glabrata isolates.

Authors:  Laura Bedin Denardi; Débora Alves Nunes Mario; Érico Silva Loreto; Janio Morais Santurio; Sydney Hartz Alves
Journal:  Braz J Microbiol       Date:  2015-03-31       Impact factor: 2.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.